Tag: information

HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is pleased to invite investors to a webinar on July 10, 2025, at 4:15 p.m. ET.

Senior Living Leader Brings Full-Spectrum Industry Experience to Guide AI Transformation Across the Sector

PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’),  a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.

WINTER PARK, Fla., July 07, 2025 (GLOBE NEWSWIRE) -- Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) today announced its second quarter and year-to-date 2025 portfolio and transaction activities and provides a balance sheet update.

VERO BEACH, Fla., July 07, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced that it will release results for the second quarter of 2025 following the close of trading on the New York Stock Exchange on Thursday, July 24, 2025.

Ningde, Fujian, China, July 07, 2025 (GLOBE NEWSWIRE) -- Oriental Rise Holdings Limited (Nasdaq: ORIS) (“Oriental Rise” or the “Company”), an integrated supplier of white- and black-tea products in mainland China, today announced that on June 30, 2025 it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid-price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

The notification resulted from the fact that the closing bid price of the Company’s ordinary shares was below US $1.00 per share for 30 consecutive business days, from May 15, 2025 to June 27, 2025. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The notice has no immediate effect on the listing of the Company’s ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker “ORIS.”

Under Nasdaq Listing Rule 5810(c)(3)(A), Oriental Rise has a 180-calendar-day compliance period, ending on December 29, 2025 (the “Compliance Period”), to regain compliance with the minimum bid-price rule. If at any time during the Compliance Period the closing bid price of the Company’s ordinary shares is at least US $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.

If the Company does not regain compliance within the initial Compliance Period, it may be eligible for an additional 180-calendar-day grace period, provided that it meets all other continued-listing criteria for the Nasdaq Capital Market (except the bid-price requirement) and notifies Nasdaq of its intention to cure the deficiency, which may include implementing a reverse stock split if necessary.

Oriental Rise is actively monitoring the bid price of its ordinary shares and is evaluating all available options to regain compliance with Nasdaq’s requirements. The Company remains committed to delivering value to its shareholders and maintaining its listing on Nasdaq.